Delisting of Securities from The Nasdaq Stock Market
Nasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and
How this was made
The 30-second read
Why it matters
This is a direct exchange action. For affected tickers, the main tradable consequence is reduced liquidity and increased execution risk, with potential forced migration to alternative venues.
Market read
Traders holding or trading these names need to reassess liquidity, venue, and execution risk immediately following Nasdaq’s delisting announcement.
What to watch
Traders should focus on what happens next for each instrument (OTC eligibility, reverse merger prospects, bankruptcy risk, and warrant exercisability), which the article does not detail.
Background
Nasdaq states it will delist multiple issuers whose securities were previously suspended and have not traded on Nasdaq since those suspension dates.
Ticker impact
Nasdaq announced it will delist CERo Therapeutics Holdings’ common stock and warrants after the securities were suspended on Oct. 31, 2025.
Near-term downside bias and elevated volatility around delisting mechanics and any remaining trading window.
The article states Nasdaq will delist the company’s securities and that they have not traded on Nasdaq since the suspension date, which typically accelerates liquidity deterioration.
Nasdaq announced delisting of Actelis Networks’ common stock after suspension on April 10, 2026.
Downward pressure and wider spreads as Nasdaq access ends.
The exchange action is explicit and the stock has not traded on Nasdaq since suspension.
Nasdaq will delist American Rebel Holdings’ common stock and warrants after suspension on May 13, 2026.
Negative bias for equity and warrant instruments.
The article states Nasdaq will delist the securities and that they have been inactive on Nasdaq since suspension.
Nasdaq announced delisting of Reviva Pharmaceuticals Holdings’ common stock after suspension on May 14, 2026.
Downward drift and elevated volatility as listing support ends.
The text is a direct Nasdaq delisting announcement with no Nasdaq trading since suspension.
Nasdaq announced delisting of REE Automotive Ltd.’s Class A Ordinary Shares after suspension on July 7, 2026.
Downward pressure and higher volatility as Nasdaq access ends.
The article states Nasdaq will delist the Class A ordinary shares and notes no Nasdaq trading since suspension.
Market effects
Broad delisting actions can signal heightened compliance stress among small-cap issuers, increasing perceived credit and liquidity risk in the segment.
Primarily impacts US-listed Nasdaq microcaps and their holders; spillover is limited but can affect OTC/alternative venue liquidity.
Limited global read-through, except for cross-listed investors who may need to adjust trading venues.
Counterpoint
If the securities already stopped trading on Nasdaq after suspension, the incremental price impact may be smaller than typical delisting headlines suggest.
Key entities
- venueNasdaq Stock Market
Exchange announcing delisting of multiple suspended issuers.
- issuerCERo Therapeutics Holdings, Inc.
Nasdaq delisting of common stock and warrants announced.
- issuerBowen Acquisition Corp.
Nasdaq delisting of ordinary shares, units, and rights announced.
- issuerGraphjet Technology
Nasdaq delisting of Class A Ordinary Shares announced.
- issuerBlue Hat Interactive Entertainment Technology
Nasdaq delisting of ordinary shares announced.
